Nov 8, 2011 . Seattle Genetics and Millennium Announce Presentation of ADCETRIS(TM) Data at

Seattle Genetics: Adcetris Panel Reconvenes (live blog). Seattle Genetics:

Health Magazines: Seattle Genetics marketed drug Adcetris was approved by the

Aug 22, 2011 . FDA granted accelerated approval of ADCETRIS brentuximab vedotin for

Seattle Genetics is a biotechnology company advancing a broad pipeline of . In

Nov 8, 2011 . Seattle Genetics and Millennium Announce Presentation of ADCETRIS(TM) Data

Nov 8, 2011 . Seattle Genetics and Millennium are jointly developing ADCETRIS. Under the terms

Aug 20, 2011 . Thank you for joining us. I am your host Yohemy Auerbach at CRWE Newswire

Safety and Prescribing Information for ADCETRIS (brentuximab vedotin.

Oct 31, 2011 . Seattle Genetics, Inc. has initiated a Phase II clinical trial of ADCETRIS, or

Aug 20, 2011 . Seattle Genetics, Inc. today announced that the U.S. Food and Drug

Oct 25, 2011 . Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that it has initiated a

Aug 19, 2011 . Seattle Genetics ($SGEN) has crossed the finish line. The FDA has granted the

Aug 19, 2011 . The FDA on Friday approved Seattle Genetics' Adcetris (brentuximab vedotin) for

Aug 19, 2011 . White Plains, NY (August 19, 2011) - Today the Food and Drug Administration (

Aug 19, 2011 . Adcetris is an antibody-drug that targets a type of lymphoma cell called CD30. It

Aug 22, 2011 . Seattle Genetics, Inc. announced that the US Food and Drug Administration (FDA

Aug 31, 2011 . Cancer Drug news. FDA grants accelerated approval of Seattle Genetics'

Aug 19, 2011 . Seattle Genetics' lymphoma drug is approved 10 days earlier than expected.

Oct 13, 2011 . In the case of Adcetris, accelerated approval will no doubt deliver a commercial

Aug 19, 2011 . Cue the Trumpets! Seattle Genetics gained FDA approval to market its antibody

ADCETRIS is a CD30-directed antibody-drug conjugate indicated for: .

Aug 22, 2011 . Shares of US biotech firm Seattle Genetics Nasdaq: SGEN) gained 8% to $15.09

After conducting channel checks, ThinkEquity believes that Seattle Genetics'

14 out of 15 patients (93 percent) achieved complete resolution of malignant

Oct 26, 2011 . Seattle Genetics, Inc. (Nasdaq: SGEN) announced that it has initiated a phase II

Sep 26, 2011 . Millennium: The Takeda Oncology Company, a wholly owned subsidiary of

Aug 19, 2011 . The Food and Drug Administration approved Seattle Genetics' Adcetris to treat

Adcetris (Brentuximab) is an investigational drug being developed by Seattle

Sep 22, 2011 . excerpt: Adcetris, from Seattle Genetics, used to treat to treat Hodgkin lymphoma

Aug 24, 2011 . Sally Church on Pharma Strategy Blog analyzes the cost of Seattle Genetics

Aug 19, 2011 . WASHINGTON (dpa-AFX) - Seattle Genetics Inc. (SGEN) Friday announced that

Aug 22, 2011 . Click an article headline for more information. Seattle Genetics Commits To

Dec 1, 2011 . Since Seattle Genetics' brentuximab vedotin (Adcetris) only arrived on the market

Aug 19, 2011 . The Food and Drug Administration approved Adcentris, from Seattle Genetics, to

Aug 22, 2011 . BioWorld Online is the news service of record for the biotechnology industry and

Nov 8, 2011 . Seattle Genetics and Millennium Announce Presentation of ADCETRIS™ Data at

Seattle Genetics to Present at Upcoming Investor Conference. 11/08/2011.

Aug 24, 2011 . Fresh off an approval for Hodgkin's lymphoma and another rare lymphoma,

Sep 14, 2011 . We know that Seattle Genetics plans to charge $13500 per dose of ADCETRIS,

Aug 19, 2011 . Seattle Genetics Inc. (SGEN) Friday announced that FDA has granted accelerated

Aug 22, 2011 . As expected, regulators in the USA have given the green light in two indications

Sep 19, 2011 . Tags : Adcetris, Adcetris sales forecast, Seattle Genetics, SGEN, SGEN stock

Aug 22, 2011 . Yet another $100000-plus cancer treatment will soon hit the market. Seattle

Nov 6, 2011 . Seattle Genetics (NASDAQ: SGEN) announced third quarter results on Thursday,

Nov 2, 2011 . The FDA has granted acceleration approval for Adcetris (brentuximba vedotin) for

ADCETRIS[tm] brentuximab vedotin. Now Approved. Download Prescribing

Nov 9, 2011 . Seattle Genetics and Millennium Announce Presentation of ADCETRISTM Data

Nov 3, 2011 . “The approval of ADCETRIS during the third quarter marked a transformative

Aug 22, 2011 . The cost per patient for Adcetris may run up to $121500 or even higher, to treat

Sitemap